Last reviewed · How we verify
Positive control vaccine 2
A positive control vaccine designed to elicit immune responses as a reference standard in clinical trials.
A positive control vaccine designed to elicit immune responses as a reference standard in clinical trials. Used for Clinical trial positive control (specific indication unknown).
At a glance
| Generic name | Positive control vaccine 2 |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Positive control vaccines are used in vaccine development studies to validate trial methodology and demonstrate that the study population can mount appropriate immune responses. This vaccine serves as a benchmark to compare the immunogenicity and safety profile of investigational vaccine candidates against a known, established vaccine control.
Approved indications
- Clinical trial positive control (specific indication unknown)
Common side effects
- Injection site reactions
- Fever
- Myalgia
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Kaiser Colorado Flu Nudge (NA)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Clinical Trial of PCV24 in Infants Aged 2-23 Months (PHASE1)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi
- A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: